Comparative Activity of Cefotaxime and Selected f3-lactam Antibiotics Against Haemophilus Influenzae and Aerobic Gram-Negative Bacilli
|
|
- Joanna Parks
- 5 years ago
- Views:
Transcription
1 REVIEWS OF INFECTIOUS DISEASES VOL. 4, SUPPLEMENT SEPTEMBER-OCTOBER by The University of Chicago. All rights reserved /82/ $02.00 Comparative Activity of Cefotaxime and Selected f3-lactam Antibiotics Against Haemophilus Influenzae and Aerobic Gram-Negative Bacilli H. J. Dabernat and C. Delmas From the Laboratories of Bacteriology and Virology, Faculty of Medicine, Centre Hospitalier Regional de Toulouse, Toulouse, France The activity of cefotaxime was compared with that of ampicillin, moxalactam, and cefoperozone against 50 isolates of Haemophilus influenzae and with that ofampicillin, carbenicillin, cephalothin, cefoxitin, cefamandole, cefazolin, and several other established and investigational f3-lactam antibiotics against several hundred isolates of gram-negative aerobic enteric bacilli. Minimal inhibitory concentrations of the drugs were determined by the agar plate dilution technique for H. influenzae and by the microtiter broth dilution technique for the other pathogens. Cefotaxime was the most active agent against H. influenzae; it was 20 times more active than ampicillin. It was also the most active agent against Escherichia coli, Klebsiella pneumoniae, nontyphoid Salmonella species, and Yersinia enterocolitica. Cefotaxime was among the most active agents against Enterobacter cloacae, Citrobacter species, Shigella species, Proteus mirabilis, and Acinetobacter calcoaceticus. None of the new cephalosporins or penicillin inhibited >90070 of the isolates of Pseudomonas aeruginosa at concentrations of 16 tjg/ml; these drugs were, however, more active than carbenicillin. Among the (J-Iactam antibiotics, ampicillin has been the most active against Haemophilus influenzae, carbenicillin and ticarcillin the most active against Pseudomonas aeruginosa, and cefuroxime and cefamandole the most active against the Enterobacteriaceae. Cefotaxime is a semisynthetic cephalosporin with great activity, a broad spectrum of antibiotic activity, and considerable (J-Iactamase stability [1-3]. This paper compares the activity of cefotaxirne with that of ampicillin, moxalactam, and cefoperazone against H. influenzae and with that of ampicillin, carbenicillin, and a wide range of cephalosporins against a variety of aerobic gram-negative enteric bacillary bacterial species. Materials and methods Organisms. Isolates of H.' influenzae capsular type B were cultured from clinical specimens (spinal fluid, blood, and sputum) taken from patients in Paris and Toulouse. Of the 50 strains, 14 were resistant to ampicillin and produced (J-Iactamase, as determined by tests with a chromogenic cephalosporin (nitrocefin, Glaxo, Please address requests for reprints to Dr. Charles E. Cherubin, The Jewish Hospital and Medical Center of Brooklyn, Room 113, 555 P.ospect Place, Brooklyn, New York Greenford, England). The isolates of Enterobacteriaceae, P. aeruginosa, and Acinetobacter calcoaceticus were cultured from a variety of clinical specimens (i.e., blood, urine, stool, sputum, pus, bile, and skin swabs), and species were determined by means of the API 20 E (API System, La Balme les Grottes, France). Susceptibility tests. The activities of the following antibiotics were tested: ampicillin (Bristol Laboratories, Paris), carbenicillin (Beecham Laboratories, Paris), cefotaxime (Hoechst-Roussel Pharmaceuticals, Paris), cephalothin (Eli Lilly, Paris), cephaloridine (Glaxo, Paris), cefoxitin (Merck Sharp & Dohme, Paris), cefamandole (Lilly), piperacillin (Lederle Laboratories, Paris), moxalactam (Lilly), mezlocillin (Bayer, Paris), cephalexin (Lilly), cefuroxime (Glaxo), ceftriaxone (Hoffmann-La Roche, Paris), and cefoperazone (Pfizer Laboratories Division, Paris). All drugs were tested against the gram-negative bacilli, whereas only ampicillin, cefotaxime, moxalactam, and cefoperazone were tested against H. influenzae. The MICs for H. influenzae were determined by the agar plate dilution method on Mueller-Hinton agar supplemented with 1070 Fildes (Difco Laboratories, Detroit, MI). Inocula of " bacteria, grown in brain heart infusion broth with 10/0 Fildes and in a late phase of growth (i.e., after incubation for 18 hr at 37 C), were applied to agar 5401
2 5402 Dabernat and Delmas plates with a multipoint replicator. The MICs were determined after incubation overnight at 37 C in air. For all other organisms, the MICs were determined in Mueller-Hinton broth by the micromethod with the MIC 2000 inoculator and dilutor (Dynatech Laboratories, Alexandria, VA). Plates were read after incubation for 18 hr at 37 C. Results The MICs of the four fj-iactam drugs tested against H. influenzae are shown in table I. All three of the new fj-iactam agents are more active than ampicillin, even against strains that do not produce fj-lactamase; the MICs of the fj-lactam agents for all isolates are <1 ug/rnl. The most active drug, by a small margin, is cefotaxime, which is about 20 times more active than ampicillin against the non-fj-lactamase-producing strains and is quite potent against enzyme-producing strains. Table 2 shows the susceptibility of the various gram-negative bacilli to the 14 antibiotics tested. Against Escherichia coli and Klebsiella pneumoniae, the newer cephalosporins (cefotaxime, moxalactam, cefoperazone, and ceftriaxone) are considerably more active than the older agents. Cefotaxime is the most active of all agents against K. pneumoniae and the second most active (after ceftriaxone) against E. coli. Some strains of E. coli appear to be resistant to cefoperazone (MIC, 32 ug/ml), and some strains of Klebsiella definitely are resistant to cefoperazone and ceftriaxone (MIC, 64 ug/ml). For the isolates of E. cloacae, the MICs of all antibiotics vary widely, although the newer agents clearly are more active. Cefotaxime, moxalactam, and ceftriaxone appear to be equally active against this organism. Similar results are seen for the isolates of Citrobacter species, with cefoperazone, the least active of the four newer agents. The results are also similar for the isolates of Shigella species, Serratia species, nontyphoid Salmonella species, Yersinia entero- colitica, and Proteus mirabilis. Although some strains of Acinetobacter calcoaceticus are extremely sensitive to the four newer agents (MIC, <0.1 ug/ml), the MIC so (i.e., the lowest concentration inhibiting growth of of tested strains) of 16 ug/rnl shows that at least half of the isolates are not nearly as sensitive as those of other species. With P. aeruginosa, an entirely different range of MICs is seen. Very wide ranges are noted for the newer agents and for carbenicillin, mezlocillin, and piperacillin. None of the four new fj-lactam agents shows a clear advantage over piperacillin. All agents except moxalactam and cefoperazone fail to inhibit some proportion of strains of P. aeruginosa (with an inoculum of 10 4 ) at a concentration of 128 ug/rnl (table 3). Discussion The results presented here demonstrate the high degree of in vitro activity of cefotaxime against H. influenzae thus confirming the results already published by other workers [4-6]. Cefotaxime not only is more active than other cephalosporins, but is even more active than ampicillin, which until now has been considered the drug of choice for the treatment of diseases caused by H. influenzae [7-9]. Cefotaxime is, in fact, 20 times more active than ampicillin and, according to the literature [6, 10], is 25 times more active than cefamandole, 150 times more active than cefoxitin and cephalothin, and 200 times more active than cefazolin and cephaloridine. Because of the low MIC values ( ug/ml) for even the fj-iactamaseproducing strains, cefoperazone, moxalactam, and particularly cefotaxime soon may become the preferred antibiotic for the treatment of infections caused by H. influenzae, even those of the central nervous system, for which their extraordinary antimicrobial activity may suit them uniquely. Against E. coli, K. pneumoniae, E. cloacae, Table 1. In vitro susceptibility of 50 isolates of Haemophilus influenzae to four antimicrobial agents. No. of isolates susceptible at indicated MIC (J.tg/ml) Agent 0.OO Ampicillin Cefotaxime Moxalactam Cefoperazone
3 Table 2. In vitro susceptibility of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter species, Shigella species, Serratia species, nontyphoid Salmonella species, Yersinia enterocolitica, Proteus mirabilis, and Acinetobacter calcoaceticus. MIC range/mic,o/mic9o (JAg/ml) for indicated organism" E. coli K. pneumoniae E. cloacae Citrobacter Shigella Agent (n = 104) (n = 1(4) (n = 81) (n = 77) (n = 40) Ampicillin 0.5->128/2/128 4->128/64/>128 1->128/128/>128 1->128/>128/> >128/2/4 Carbenicillin 1->128/4/128 1->128/128/>128 1->128/8/>128 1->128/>128/>128 1->128/4/8 Mezlocillin 0.5->128/2/ >128/8/>128 1->128/4/>128 1->128/>128/> >128/2/4 Piperacillin 0.12->128/1/ >128/8/> >128/4/>128 1->128/>128/> >128/1/2 Cephalothin 1->128/8/ >128/4/64 2->128/>128/>128 1->128/>128/> /8/8 Cefazolin 1->128/2/ >128/2/32 8->128/>128/>128 4->128/>128/>128.../.../... Cephalexin 2->128/4/16 4->128/4/8 4->128/128/>128 4->128/64/> /8/8 Cefamandole 0.12->128/0.5/ >128/1/ >128/8/> >128/4/ /0.25/0.5 Cefuroxime 0.5->64/2/ >128/2/4 1->128/8/ >128/2/8 1-16/2/4 Cefoxitin 1-128/2/ /2/4 2->128/64/>128 1->128/64/ /214 Cefotaxime /0.06/ /0.06/ /0.12/ /0.12/ /0.03/0.06 Moxalactam / / / / /0.06/0.12 Cefoperazone / /0.5/ /0.25/ /4/ /0.12/0.25 Ceftriaxone /0.03/ /0.03/ /0.25/ /0.12/ /0.03/0.06 MIC range/ml'co./ml'cs, (jjg/ml) for indicated organism" Nontyphoid Serratia Salmonella Y. enterocolitica P. mirabilis A. calcoaceticus Agent (n = 80) (n = 50) (n = 22) (n = 76) (n = 65) Ampicillin 4->128/>128/> >128/1/2 4-16/8/ >128/1/> >128/128/>128 Carbenicillin 1->128/>128/>128 2->128/4/8 1->128/128/ >128/1/>128 2->128/32/>128 Mezlocillin 2->128/ 128/>128 1->128/4/4 or /0.5/ >128/1/>128 2->128/64/>128 Piperacillin 1->128/ 128/> >128/214 or /1/ >128/0.25/>128 1->128/321>128 Cephalothin 128->128/>128/>128 1->128/2/8 8-64/16/ /4/32 8->128/>128/>128 Cefazolin >128/>128/> /1/2 2-8/4/4 2-32/4/32 16->128/>128/>128 Cephalexin.../.../ /8 4-8/4/8 8->128/16/32 8->128/>128/>128 Cefamandole 2->128/128/> >128/0.5/ /0.5/ >128/1/16 4->128/128/>128 Cefuroxime 8->128/128/> /4/ /0.5/ /1/2 2->128/ Cefoxitin 4->128/16/ /2/ /2/8 1-8/2/4 2->128/64/>128 Cefotaxime /0.5/ /0.06/ / /0.015/ /16/32 Moxalactam /0.25/ /0.06/ /0.03/ / /32/64 Cefoperazone /16/ >128/0.25/ /1/ /0.5/ /64/64 Ceftriaxone /0.5/ / /0.015/ /0.015/ /16/32 The MIC,o and MIC90 are the lowest concentrations inhibiting growth of and 90% of tested strains, respectively. g I::l (;;.... o :::I : s :::I.. C/) w
4 S404 Dabernat and Delmas Table 3. In vitro susceptibility of Pseudomonasaeruginosa(n 34). Agent MIC range MIC so MIC 90 Ampicillin >128 >128 >128 Carbenicillin 32-> >128 Mezlocillin 16-> >128 Piperacillin 2-> Cephalothin >128 >128 >128 Cefazolin >128 >128 >128 Cephalexin >128 >128 >128 Cefamandole >128 >128 >128 Cefuroxime >128 >128 >128 Cefoxitine 64->128 >128 >128 Cefotaxime 8-> >128 Moxalactam 8-> Cefoperazone 2-> Ceftriaxone 8-> >128 NOTE. MIC so and MIC 90 = the concentration of drug required to inhibit and 90010, respectively, of the isolates. Values are given as /Ag/ml. Serratia species, P. mirabilis, nontyphoid Salmonella species, Shigella species, and Yersinia enterocolitica, the four new (J-Iactam agents (moxalactam, cefotaxime, cefoperazone, and ceftriaxone) are much more active than the older cephalosporins already in clinical use. Cefoperazone is the least active of the four; a few isolates of nearly every species have MIC values that may indicate clinical resistance. Cefotaxime is either the most active or equal in activity to ceftriaxone and moxalactam against the strains tested. Against A. calcoaceticus, the four new agents are more active than the older ones, but by a much smaller margin. At least of the isolates are sensitive only to 32 or 64 ug/rnl. Unless large doses of the agents are used, these isolates probably should be considered clinically resistant. Against P. aeruginosa, the large margin between the activity of older and newer agents does not exist; cefotaxime, moxalactam, cefoperazone, and ceftriaxone appear to be slightly more active than carbenicillin and mezlocillin and slightly less active than piperacillin. Our findings agree with the extensive literature on the antimicrobial activity of the latter agents [11-17]. Since none of these older agents is presently considered appropriate for monotherapy in severe infections due to P. aeruginosa or even for therapy before sensitivity testing in minor infections, the new agents will probably be inappropriate also in such instances. The possible synergy of the new (3-lactam agents must be studied and any synergistic effects confirmed in vivo. References 1. Chabbert, Y. A., Dang Van, A., Labia, R. Comparative antibacterial activity of HR 756, a syn isomer of a methoxy-imino cephalosporin [abstract no. 76]. In Proceedings of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Oct. 1-2, American Society for Microbiology, Washington, D.C., Fu, K. P., Neu, H. C. Beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob. Agents Chemother. 14: , Peronnet, J., Bucourt, R., Heymes, R., Bormann, D., Durckheimer, W. Chemical and physicochemical profiles of the new cephalosporin derivative HR 756 [abstract no. 75]. In Proceedings of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Oct. 1-2, American Society for Microbiology, Washington, D.C., Drasar, F. A., Farrell, W., Howard, A. J., Hince, c., Leung, T., Williams, J. D. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and gramnegative rods. J. Antimicrob. Chemother. 4: , Hamilton-Miller, J. M. T., Brumfitt, W., Reynolds, A. V. Cefotaxime (HR 756), a new cephalosporin with exceptional broad-spectrum activity in vitro. J. Antimicrob. Chemother. 4: , Dabernat, H. J., Buu-Hoi-Dang Van, A., Delmas, c., Bauriaud, R. Comparative activities of cefotaxime, a new cephalosporin derivative, and of selected beta-lactam antibiotics against Haemophilus species. Ann. Microbiol. (Paris) 130A: , Jorgensen, J. H., Alexander, G. A. Comparative activities of selected beta-iactam antibiotics against Haemophilus influenzae. Antimicrob. Agents Chemother. 13: , Kattan, S., Cavanagh, P., Williams, J. D. Relationship between f3-lactamase production by Haemophilus influenzae and sensitivities to penicillins and cephalosporins. J. Antimicrob. Chemother. 1:79-84, Wise, R., Rollason, T., Logan, M., Andrews, J. M., Bedford, K. A. HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob. Agents Chemother. 14: , Dabernat, H., Bauriaud, R., Delmas, c., Lefevre, J. c., Lemozy, J., Lareng, M. B. Sensibilite d'haemophilus influenzae a huit antibiotiques. Isolement de souches multi-resistantes, Medecine et Maladies Infectieuses 8: , Fu, K. P., Neu, H. C. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob. Agents Chemother. 13: , Fu, K. P., Neu, H. C. Piperacillin, a new penicillin active
5 Comparison with f3-lactam Antibiotics S405 against many bacteria resistant to other penicillins. Antimicrob. Agents Chemother. 13: , Kuck, N. A., Redin, G. S. In vitro and in vivo activity of piperacillin, a new broad-spectrum semisynthetic penicillin. J. Antibiot. 31: , Moody, M., Morris, M., Young, V. Schimpff, S. Comparison of four anti-pseudomonas cephalosporin-like antibiotics with cephalothin [abstract no. 164]. In Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Oct International Society of Chemotherapy and American Society for Microbiology, Washington, D.C., Morel, C., Monrocq, N. T 1551, a new semisynthetic cephalosporin: a comparative in vitro study against 630 clinical isolates [abstract no. 409]. In Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Oct International Society of Chemotherapy and American Society for Microbiology, Washington, D.C., Neu, H. c., Aswapokee, N., Fu, K. P., Aswapokee, P. Antibacterial activity of a new l-oxa cephalosporin compared with that of other f3-lactam compounds. Antimicrob. Agents Chemother. 16: , Williams, R. J., Williams, J. D. Activity of three cephalosporins and an oxa-beta-iactam against Pseudomonas aeruginosa [abstract no. 140]. In Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Oct. 1-5, International Society of Chemotherapy and American Society for Microbiology, Washington, D.C., 1979.
Against Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationSusceptibility of Cephalothin-Resistant Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEmOTHERAPY, Mar. 1978, p. 484489 0066-4804/8/0013-0484$02.00/0 Copyright 1978 American Society for Microbiology Vol. 13, No. 3 Printed in U.S.A. Susceptibility of Cephalothin-Resistant
More informationCephalosporin, Against Cephalosporin-Resistant Bacteria, and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1979, P. 59-553 Vol. 16, No. 5 66-/79/11-59/$2./ Antibacterial Activity of Ceftizoxime (FK 79), a New Cephalosporin, Against Cephalosporin-Resistant Bacteria,
More informationTreatment of serious Pseudomonas infections with azlocillin
Journal of Antimicrobial Chemotherapy (983), Suppl. B, 53-58 Treatment of serious Pseudomonas infections with azlocillin S. Olive, W. J. Mogabgab, B. Holmes, B. Pollock, B. Pauling and R. Beville Tulane
More informationRecommendations for Dilution Susceptibility Testing Concentrations of the Cefoperazone-Sulbactam Combination
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1987. p. 1725-1729 0095-1137/87/091725-05$02.00/O Copyright (O 1987, American Society for Microbiology Vol. 25, No. 9 In Vitro Antimicrobial Spectrum, Occurrence
More informationThe activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
Journal of Antimicrobial Chemotherapy (984) 4, Suppl. B, 39-43 The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
More informationFig 1. p-lactamase activity of cell extract from the culture of E. cloacae H-27
CPZ or CMZ was added to the cultures at the start of cultivation. Ĉ-lactamase activity was determined by spectrophotometry using CER(100pM) as a substrate. Fig 1. p-lactamase activity of cell extract
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMezlocillin for Treatment of Infections in Cancer Patients
ANTIMICROBIAL AGENTs A CHEMOTHERAPY, June 98, p. 8- -8/8/-8/$./ Vol. 7,. Mezlocillin for Treatment of Infections in Cancer Patients BRIAN F. ISSELLt A GERALD P. BODEY* Department ofdevelopmental Therapeutics,
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationEfficacy of Ceftriaxone in Serious Bacterial Infections
ANTIMIROBIAL AGENTS AND HEMOTHERAPY, Mar 1982, p 402-406 0066-4804/82/030402-05$0200/0 Vol 21, No 3 Efficacy of eftriaxone in Serious Bacterial Infections JAY S EPSTEIN, SUSAN M HASSELQUIST, AND GARY L
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationEVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS
Indian Journal of Medical Microbiology, (2005) 23 (2):120-124 Brief Communication EVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS S Singhal, T
More informationSynergism of Fosfomycin-Ampicillin and Fosfomycin-
ANTIMICROBiAL AGENTS AND CHEMoTHERAPY, May 1978, p. 75-79 66-484/78/13-75$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 5 Printed in U.S.A. Synergism of Fosfomycin-Ampicillin and Fosfomycin-
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationSensitivity of Gram-negative bacilli to ampicillin
J. clin. Path. (1969), 22, 644-648 Sensitivity of Gram-negative bacilli to ampicillin after six years' clinical use B. SLOCOMBE AND R. SUTHERLAND From Beecham Research Laboratories, Brockham Park, Betchworth,
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationCeftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)
COMPOSITION Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection) CEFTOMAX - S Injection 1.5 gm Each vial contains: Cefoperazone Sodium equivalent to Cefoperazone IP. 1,000 mg Sulbactam Sodium
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationCefoperazone Disk Diffusion Susceptibility Test: Confirmation
JOURNAL OF CLINICAL MICROBIOLOGY, May 1982, p. 777-786 0095-1137/82/050777-10$02.00/0 Vol. 15, No. 5 Cefoperazone Disk Diffusion Susceptibility Test: Confirmation of the Tentative Interpretive Criteria,
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationDiscrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis
Journal of Medical Microbiology (2004), 53, 879 885 DOI 10.1099/jmm.0.45655-0 Short Communication Correspondence Itzhak Brook ib6@georgetown.edu Received 1 March 2004 Accepted 18 May 2004 Discrepancies
More informationExperimental Endocarditis Caused by Streptococcus sanguis:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1981, p. 1-14 66-484/81/71-5$2./ Vol. 2, No. 1 Experimental Endocarditis Caused by Streptococcus sanguis: Single and Combined Antibiotic Therapy MARIA V. VICENTE,
More informationCaused by a 3-Lactamase-Producing Strain of KI-Positive Escherichia coli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1990, p. 697-701 0066-4804/90/050697-05$02.00/0 Copyright 1990, American Society for Microbiology Vol. 34, No. 5 Evaluation of - in Experimental Meningitis Caused
More informationSusceptibilities of Nonfermenters Other than Pseudomonas aeruginosa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, OCt. 1979, p. 434438 0066-4804/79/10-0434/05$02.00/0 Vol. 16, No. 4 Effect of Divalent Cation Concentrations on the Antibiotic Susceptibilities of Nonfermenters Other
More informationIn Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria
In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***
More informationHaemophilus influenzae from four laboratories in one Canadian City
Journal of Antimicrobial Chemotherapy (988), -9 Haemophilus influenzae from four laboratories in one Canadian City Julie Righter" and Ingrid Luchstnger* 'Department of Microbiology, University of Toronto;
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationTHE USE OF CEFOTAXIME IN SERIOUS AND PROBLEM SURGICAL INFECTIONS
Med. J. Malaysia Vol. XXXV No., September 980 THE USE OF CEFOTAXIME IN SERIOUS AND PROBLEM SURGICAL INFECTIONS M.BALASEGARAM M.R.DEVANAND BALWANT SINGH SUMMARY Cefotaxime [HR 756], a third generation cephalosporin
More informationMAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1)
MAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1) 1. NAME OF MEDICINAL PRODUCT MAGNEX 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sulbactam sodium/cefoperazone sodium combination is available
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationEnhancing Effect on Alkalinization of the Medium
Appum MICROBIOLOGY, Sept. 968, p. 88-9 Copyright @ 968 American Society for Microbiology Vol. 6, No. 9 Printed in U.S.A. Enhancing Effect on Alkalinization of the Medium on the Activity of Erythromycin
More informationPharmacokinetics of Cefotaxime
ANTMCROBAL AGENTS AND CHEMOTHERAPY, Nov. 1979, p. 592-597 0066-4804/79/11-0592/06$02.00/0 Vol. 16, No. 5 Pharmacokinetics of Cefotaxime KWUNG P. FU,' PRAST ASWAPOKEE,' RWN HO,2 CHARLES MATTHJSSEN,2 AND
More informationDownloaded from ismj.bpums.ac.ir at 10: on Friday March 8th 2019
- ( ) - * :... (MDR) (ESBLs: Extended-Spectrum Beta Lactamases). :.. (CLSI:Clinical and Laboratory Standards Institute). ESBL. combined disk method ESBL : / / / / / B / ( /). / / combined disk method.
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationPharmacokinetics and Bacteriological Efficacy of Moxalactam
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1980, p. 406-411 0066-4804/80/03-0406/06$020/0 Vol. 17, No. 3 Pharmacokinetics and Bacteriological Efficacy of Moxalactam (LY127935), Netilmicin, and Ampicillin
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationChapter 4. Anti-bacterial studies of PUFA extracts from Sardinella longiceps and Sardinella fimbriata. 4.1 Introduction
Anti-bacterial studies of PUFA extracts from Sardinella longiceps and Sardinella fimbriata C o n t e n t s 4.1 Introduction 4.2 Materials and Methods 4.2.1 Extract Preparation and Determination of PUFA
More informationJAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationClinical experience with ceftazidime in urology in Japan
Journal of Antimicrobial Chemotherapy (98), Suppl. A, 6- Clinical experience with ceftazidime in urology in Japan Noboo Kawamura Department of Urology, Tokai University, School of Medicine, Bosei-dai,
More informationTwice daily ceftriaxone therapy for serious bacterial infections in children
Journal of Antimicrobial Chemotherapy (1984) 13, 511-516 Twice daily ceftriaxone therapy for serious bacterial infections in children Tasnee Chonmaitree*, Blaise L. Congenif, Jose Munoz+, Tamara A. Rakusan*,
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationJOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p Vol. 36, No. 9. Copyright 1998, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p. 2575 2579 Vol. 36, No. 9 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Can Results Obtained with Commercially
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationComparison Between Agar and Broth Minimum Inhibitory Concentrations of Cefamandole, Cefoxitin, and Cefuroxime
ANTMCROBAL AGENTS AND CHEMOTHERAPY, Apr 1979, p 572-579 0066-4804/79/00572/08$0200/0 Vol 15, No4 Comparison Between Agar and Broth Minimum nhibitory Concentrations of Cefamandole, Cefoxitin, and Cefuroxime
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationincluding some caused by gram-negative bacilli. These studies
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1985, p. 246-251 0066-4804/85/020246-06$02.00/0 Copyright C 1985, American Society for Microbiology Vol. 27, No. 2 Efficacy and Safety of Aztreonam-Clindamycin
More informationPrevalence of ESBL producing enterobacteriaceae in diabetic foot ulcers
Original Research Article Prevalence of ESBL producing enterobacteriaceae in diabetic foot ulcers Anitha S 1*, Natarajan V 2 1 Post Graduate, 2 Professor and HOD Department of Microbiology, Rajah Muthiah
More informationBacteriological Profile of Post Traumatic Osteomyelitis in a Tertiary Care Centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 1 (2017) pp. 367-372 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2017.601.044
More informationCefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints
INVITED ARTICLE MEDICAL MICROBIOLOGY L. Barth Reller and Melvin P. Weinstein, Section Editors Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints John D. Turnidge
More informationZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul
Published on: 10 Jul 2014 ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul Composition ZOSUL Injection 1.0 g Each vial contains: Cefoperazone
More informationCerebrospinal Fluid Penetration of Imipenem and Cilastatin (Primaxin) in Children with Central Nervous System Infections
ANTIMIWROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1986, p. 670-674 0066-4804/86/040670-05$02.00/0 Copyright X 1986, American Society for Microbiology Vol. 29, No. 4 Cerebrospinal Fluid Penetration of Imipenem
More informationSensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the
JCM Accepts, published online ahead of print on 20 August 2014 J. Clin. Microbiol. doi:10.1128/jcm.02369-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Sensitivity of Surveillance
More informationClinical Evaluation of Moxalactam
ANTIUCROBIAL AGENTS AND CHEMOTHERAPY, JUly 1981, p. 88-97 0066-4804/81/070088-10$02.00/0 Vol. 20, No. 1 Clinical Evaluation of Moxalactam W. K. LIVINGSTON, A. M. ELLIOTT, W. E. DISMUKES, C. K. AVENT, AND
More informationDevelopment of a phenotypic method for fecal carriage detection of OXA-48-producing
JCM Accepts, published online ahead of print on 11 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00055-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationNETILMICIN SUMMARY OF PRECLINICAL MICROBIOLOGICAL STUDIES. G. H. MILLER, R. S. HARE, E. L. Moss, Jr., F. J. SABATELLI and J. A.
NETILMICIN SUMMARY OF PRECLINICAL MICROBIOLOGICAL STUDIES G. H. MILLER, R. S. HARE, E. L. Moss, Jr., F. J. SABATELLI and J. A. WAITZ Departments of Chemotherapy and Antibiotic Research Schering Corporation
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationRandomized Prospective Study Comparing Moxalactam and Cefoxitin with or without Tobramycin for the Treatment of Serious Surgical Infections
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1986, p. 244-249 0066-4804/86/020244-06$02.00/0 Copyright C 1986, American Society for Microbiology Vol. 29, No. 2 Randomized Prospective Study Comparing Moxalactam
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationClinical and In Vitro Evaluation of Cefazolin, a New Cephalosporin Antibiotic
ANTMICROBIAL AGZNTS AND CHEMOTHERPY, Feb. 1973, p. 168174 Copyright 1973 American Society for Microbiology Vol. 3, No. 2 Printed in U.S.A. Clinical and In Vitro Evaluation of Cefazolin, a New Cephalosporin
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationUrinary Tract Infections and Their Effects on the Urogenital and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1986, p. 107-111 Vol. 29, No. 1-0066-4804/86/010107-05$02.00/0 Copyright 1986, American Society for Microbiology Amoxicillin-Clavulanic Acid Versus Cefaclor
More informationMINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Patient Information Leaflet
No. 851 of August 19, 2014 КЛС No. 10 of July 31, 2014 Invented trade name: Cefosulbactam MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS Patient Information Leaflet CEFOSULBACTAM (ЦЕФОСУЛЬБАКТАМ) Powder
More informationRoula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon
http://skinnywithfiber.org Roula M. Abdel-Massih Dept. of Biology, University of Balamand, Lebanon Ilex paraguariensis Classification and characteristics Family Aquifoliaceae Found mainly in South America
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationClinical Microbiology Newsletter
Clinical Microbiology Newsletter $88 Vol. 30, No. 10 www.cmnewsletter.com May 15, 2008 Newer β-lactamases: Clinical and Laboratory Implications, Part I * Ellen Smith Moland, B.S.M.T., Soo-Young Kim, M.D.,
More informationFAECAL WELL D-ONE. System for the presumptive identification and antibiotic susceptibility of pathogenic microorganisms of the intestinal tract.
System for the presumptive identification and antibiotic susceptibility of pathogenic microorganisms of the intestinal tract. 1. INTRODUCTION Intestinal and gastrointestinal infections are a fairly common
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationInfectious Disease Testing. UriSelect 4 Medium. Direct Identification Visibly Reliable
Infectious Disease Testing Urielect 4 Medium Direct Identification Visibly Reliable Urielect 4 Non selective chromogenic medium for the isolation, differentiation and enumeration of urinary tract infections
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationDetection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry
JCM Accepts, published online ahead of print on 2 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.01002-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationAerobic bacteria isolated from diabetic septic wounds
Aerobic bacteria isolated from diabetic septic wounds Eithar Mohammed Mahgoub*, Mohammed Elfatih A. Omer Faculty of Pharmacy, Omdurman Islamic University Department of Pharmaceutical Microbiology, Omdurman
More informationCEFOBID (sterile cefoperazone, USP) Formerly known as sterile cefoperazone sodium, USP
CEFOBID (sterile cefoperazone, USP) Formerly known as sterile cefoperazone sodium, USP PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION DESCRIPTION CEFOBID (cefoperazone), formerly known as cefoperazone sodium,
More informationBACTERIOLOGY PROFICIENCY TESTING PROGRAM
BACTERIOLOGY PROFICIENCY TESTING PROGRAM Comprehensive Category January 14, 2013 If you have any questions or comments, please contact either: Dr. Wendy Archinal Dr. Kimberlee Musser Phone: (518) 474-4177
More informationEvaluation of Antibacterial Effect of Odor Eliminating Compounds
Evaluation of Antibacterial Effect of Odor Eliminating Compounds Yuan Zeng, Bingyu Li, Anwar Kalalah, Sang-Jin Suh, and S.S. Ditchkoff Summary Antibiotic activity of ten commercially available odor eliminating
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationAMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA. Mohamudha Parveen R., Harish B.N., Parija S.C.
Brazilian Journal of Microbiology (2010) 41: 596-602 ISSN 1517-8382 AMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA Mohamudha Parveen R., Harish B.N., Parija
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationComparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 7 Ver. X (July. 2016), PP 01-05 www.iosrjournals.org Comparision of Antibiotic Susceptibility
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationThis material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More informationPharmacokinetics and Cerebrospinal Fluid Bactericidal Activity of Ceftriaxone in the Treatment of Pediatric Patients with Bacterial Meningitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1982, p. 622-627 0066-4804/82/100622-06$02.00/0 Copyright 0 1982, American Society for Microbiology Vol. 22, No. 4 Pharmacokinetics and Cerebrospinal Fluid Bactericidal
More information